Recent Finacing
Recent Raise
Esanex develops SNX‑5422, an Hsp90 inhibitor from Serenex, advancing it into clinical development with phase‑1 safety studies in solid tumors and phase‑2 trials in blood cancers.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
